• Monthly Archives: March 2011

    Atomoxetine Improves Memory and Attention in Peri- and Postmenopausal Women

    Many peri- and post-menopausal women describe problems with memory and attention.  Data regarding the use of estrogen replacement therapy to improve cognitive functioning has been mixed.  Furthermore, recent concerns regarding the long-term risks of ERT have limited its use.  A recent report from C. Nell Epperson and colleagues from the University Of Pennsylvania School Of Medicine indicates that atomoxetine (Strattera), a treatment for attention-deficit/hyperactivity disorder (ADHD), may improve attention and reduce memory difficulties in perimenopausal and postmenopausal women.

    Methadone and Breastfeeding

    Up until 2001, the American Academy of Pediatrics (AAP) recommended that methadone was compatible with breastfeeding in women taking less than 20 mg per day.  Because most women on methadone maintenance therapy typically require 50 to 15o mg of methadone per day during pregnancy, this meant that most women on methadone were not able to breastfeed. However, the dose restriction for methadone was eliminated in 2001, a decision driven by several studies indicating that the levels of methadone secreted into human breast milk were relatively low.

    New FDA Warning on the Use of Antipsychotic Medications in Pregnancy

    On February 22, 2011, the U.S. Food and Drug Administration (FDA) informed healthcare professionals that drug labels for the entire class of antipsychotic drugs have been updated to include warnings regarding the use of antipsychotic drugs during pregnancy. The new drug labels now contain more details on the potential risk for abnormal muscle movements (extrapyramidal signs or EPS) and withdrawal symptoms in newborns exposed to these drugs during the third trimester of pregnancy.

    Go to Top